Abstract: Four group A streptococcal glyco-lipopeptide vaccine candidates were prepared and characterized, each possessing different lipidic adjuvanting moieties. The immunogenicity of the compounds was evaluated by macrophage and dendritic cell uptake studies and by in vivo quantification of systemic IgG antibody using ELISA. Three of the four vaccine candidates showed a significant induction of IgG response compared to a negative control.
Introduction
Adjuvants are important immuno-stimulatory components of vaccines, which significantly boost immune responses towards antigens. Adjuvant development has progressed slowly in the past decades, with aluminum salts being the most common adjuvants in use. [1] Recently, research efforts have focused on the development of adjuvants that activate pattern recognition receptors (PRRs) found on immune cells. PRRs recognize conserved pathogen-associated molecular patterns. This leads to the activation of cells of the innate and adaptive immune system, resulting in significantly enhanced immune responses. [2] By preparing agonists for a particular type of PRR (e.g. Toll-Like Receptor (TLR)), an appropriate immune response can be induced for each type of pathogen. [3] TLR2 is present on cells of the innate and adaptive immune system. It recognizes conserved lipidic structural components of bacteria, fungi and viruses, and plays a key role in the body's defenses, particularly against gram positive bacteria. [4] Research efforts within our group have shown that a short sequence of synthetic lipo-amino acids (LAAs), referred to as the Lipid Core Peptide (LCP), can bind to TLR2, which results in increased immune responses to otherwise poorly immunogenic peptide antigens. [5] The LCP has been combined with multiple copies of B cell epitopes from Streptoccus pyogenes in an effort to develop a fully synthetic self-adjuvanting vaccine against this pathogen.
[ [5] [6] [7] [8] [9] S. pyogenes is a Gram-positive bacterium that affects the skin and upper respiratory tract, and causes a range of health issues that are collectively referred to as group A streptococcal (GAS) infections. [10] The most severe GAS related problems are post-streptococcal rheumatic fever and rheumatic heart disease, which account for over half a million deaths annually. [11] Carbohydrates have been shown to be important in vaccine development and peptide delivery. [12] Recently, we reported a new synthetic methodology for the preparation of large, multi-component carbohydrate core vaccine candidates against GAS. [13] First, glyco-lipopeptides were prepared, which contained a lipidic adjuvanting sequence, followed by a known promiscuous T-helper epitope (PADRE), and terminated with a tetra-propargyl glucose (TPGlc) moiety. The lipidic adjuvanting sequence contained three lipidated lysine residues and was a simplified version of the LCP system. This adjuvanting sequence was employed for the purpose of developing the synthetic methodology. The final vaccine candidate (J8-Glc-PADRE-lipid) was constructed by employing the Huisgen copper-catalyzed azide-alkyne cycloaddition "click" reaction (CuAAC) [14] to couple four copies of a GAS B cell epitope, known as J8. [13] The J8 B cell epitope (sequence; QAEDKVKQSREAKKQVEKALKQLEDKVQ) was identified from the conserved C-terminal region of the M protein (a cell surface protein and a major virulence factor) of S. pyogenes. [15] It was shown to elicit systemic IgG antibodies, which were capable of opsonizing the GAS pathogen and inducing protective immunity against GAS. The J8 epitope has been employed previously in a number of studies. [8, [16] [17] [18] [19] Although B cells may be activated via a number of T cellindependent routes, the T cell-dependent activation of B cells can lead to a stronger, more long-term immune response.
[2] The PADRE T-helper epitope (Pan DR Epitope; KFVAAWTLKAA) has been shown to be recognized by a high percentage of the human population, and is thus referred to as a promiscuous T-helper epitope. [20] Incorporation of this epitope should allow for T celldependent activation of B cells, and lead to a stronger and longer lasting immune response. The synthetic approach used to synthesize the J8-Glc-PADRElipid gave vaccine candidates of increased complexity compared
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For internal use, please do not delete. Submitted_Manuscript to those prepared previously, [8] yet purification of the final vaccine candidates was more readily achieved. [13] In the current study, a similar synthetic approach was employed to prepare four novel vaccine candidates, with each containing a different lipidic adjuvanting moiety. The uptake of antigens by professional antigen-presenting cells is crucial for the initiation of a fully developed, long-term immune response. [21] Dendritic cell (DC) and macrophage uptake assays were performed to determine which of the vaccine candidates could be taken up most efficiently. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) were employed to determine particle size of the vaccine candidates. The M protein of GAS possesses an α-helical secondary structure, therefore, circular dichroism (CD) was employed to assess the secondary structure of the vaccine candidates. The immunogenicity of the four vaccine candidates was evaluated by carrying out enzymelinked immunosorbent assays (ELISAs) of blood taken from immunized mice. 
Results and Discussion

Design
In order to efficiently prepare the target set of compounds (1a-d, Figure 1 ), the methodology reported previously [13] was further developed so that branched systems could be prepared. Four vaccine candidates were synthesized, each containing the PADRE T-helper epitope and four copies of the J8 B cell epitope conjugated to the TPGlc scaffold. However, each contained a different lipidic adjuvanting moiety (Figure 1 ). Compound 1a contained the LCP adjuvanting system. Vaccine candidates have previously been prepared containing this lipidic sequence, as well as, multiple copies of the J8 epitope on a polylysine scaffold. [22] Mice immunized with these vaccine candidates gave high J8-specific antibody titers after the final boost. The induced antibodies were capable of opsonizing a number of different GAS strains [18] and immunized mice displayed protective immunity when challenged in vivo with GAS. [17] Following structure-activity relationship studies about the number of LAAs and their chain length, the LCP adjuvant was developed into the lipidic adjuvanting sequence in compound 1b (Figure 1 ), herein referred to as Lipid Core Peptide 2 (LCP2). [6, 23] Immunization with constructs containing the LCP2 adjuvanting sequence resulted in antibody titers that were comparable to that of constructs containing the LCP lipidic adjuvant. [6] The lipidic adjuvant contained in 1c (LLCP; Lysine Lipid Core Peptide) was recently reported as a simplified version of the LCP. [13] This adjuvanting system was used for the purpose of developing a novel synthetic methodology and, until now, has not been immunologically evaluated. The adjuvanting properties of similar systems containing palmitoyl lysines have been reported by Huang et al., but notable immunological responses could only be achieved by incorporating the constructs into liposomes or oilemulsions. [24] The final compound, 1d, contained a lipidic adjuvant that bears close structural resemblance to the well-known 2,3-dipalmitoyl-Sglycerylcysteine (Pam2Cys) lipidic adjuvanting moiety ( Figure  2 ). [25] [26] [27] The dipalmitoyl serine (DPS) adjuvant can be easily synthesized as an enantiomerically pure moiety, using standard solid phase peptide synthesis (SPPS), from readily available starting materials. Recently, we demonstrated that the DPS adjuvanting moiety showed strong binding affinity to the extracellular domain of the TLR2. [28] Figure 2. Pam2Cys as it appears in the TLR2 active site [29] and the DiPalmitoyl Serine (DPS) adjuvant in a similar conformation.
Synthesis
The synthesis of the target compounds began by growing a peptide sequence consisting of two lysine residues followed by the PADRE T-helper epitope [20] and an additional two lysine residues. The side chain of the terminal lysine amino acid was protected with an ivDde group (Scheme 1). The ivDde group can be selectively removed using dilute hydrazine and is commonly employed when synthesizing branched peptides. [30] Unless otherwise stated, amino acids were coupled using standard microwave assisted Fmoc SPPS and commercially available Fmoc protected amino acids (see Experimental section). The PADRE T-helper epitope was flanked by additional lysine residues in order to increase the hydrophilicity of glyco-lipopeptides, thus improving their solubility. The TPGlc carbohydrate building block was prepared using a previously reported synthesis [13] and was coupled to the N-terminus of the peptide. Almost quantitative coupling was achieved when the TPGlc and diisopropyl ethyl amine (DIPEA) were added to the resin with stirring, followed by the addition of the HBTU coupling reagent. The ivDde protecting group was then selectively removed from the lysine side chain using the standard conditions of 2% hydrazine in DMF. [30] A standard Fmoc protected lysine was coupled and the resin bound glycopeptide 2 was dried under vacuum. The glycopeptide 2 was divided into four equal portions so that all four target compounds could be synthesized from one glycopeptide. This approach is more efficient compared to the non-branched approach reported previously, [13] since glycopeptide 2, consisting of the T-helper epitope and the TPGlc carbohydrate scaffold, needed to be synthesized only once. Similarly, by removing the ivDde group prior to dividing the resin, this relatively lengthy deprotection needed to be performed only once. After dividing the resin, the lysine Fmoc protecting group was removed using piperidine, and the lipidic adjuvanting moiety could be incorporated (Scheme 2). The lipidic adjuvanting moieties of glyco-lipopeptides 3a and 3b have been prepared previously using Boc [6, 8] or Dde [31] protected synthetic LAAs. In this case, Dde protected LAAs were employed (Dde-C12-OH, Dde-C16-OH) and prepared according to the procedure of Ross et al. [32] The lipidated lysine amino acid (FmocScheme 1. Synthesis of the resin bound glycopeptide 2.
10.1002/cbic.201600639 ChemBioChem K(C12)-OH) was synthesized according to the procedure reported by Fagan et al., [13] and was used to prepare the lipidic sequence of glyco-lipopeptide 3c by standard Fmoc SPPS. The DPS lipidic adjuvanting moiety of glyco-lipopeptide 3d was prepared by coupling two standard Fmoc protected serine amino acids (Fmoc-Ser(tBu)-OH) (Scheme 3). These amino acids were incorporated so that the adjuvanting sequence of 3d was analogous to that of 3b. A third Fmoc protected serine was coupled; however, its side chain hydroxyl group was unprotected. To avoid unwanted ester formation the amino acid (Fmoc-Ser-OH) and DIPEA were added with stirring to the resin, followed by the addition of HBTU. Following Fmoc removal, the terminal amine and the unprotected side chain hydroxyl group were simultaneously lipidated using a mixture containing palmitic acid, diisopropyl carbodiimide (DIC), and dimethylaminopyridine (DMAP). The protocol completely avoids solution phase synthesis of building blocks and leads to an enantiomerically pure product. Each glyco-lipopeptide (3a-d) was cleaved from the resin using standard Fmoc SPPS cleavage conditions. Following cleavage from the resin, the glyco-lipopeptides were used without purification in the final step. The CuAAC [14] reaction was employed to conjugate four copies of the J8 B cell epitope to each of the glyco-lipopeptides 3a-d (Scheme 4). The azide functionalized J8 B cell epitope (N3-J8) was prepared using standard Fmoc SPPS, as described previously. [13] The cycloadditon reaction between the crude glyco-lipopeptides 3a-d and N3-J8 was performed according to the procedure reported by Urbani et al. [33] As the reaction proceeded, a blue/green color appeared. The reaction was deemed to be complete when the color was first distinguishable (approx. 1-2 h), at which point the reaction was cooled in a bath of dry ice and filtered to remove the copper wire. The target vaccine candidates 1a-d were purified by preparative reverse phase (RP) HPLC using a C4 column in 12-32% yield, and were characterized by mass spectrometry and analytical RP-HPLC (see supplementary materials). The particle size of the four vaccine candidates was determined by DLS and TEM. The compounds were dissolved in phosphate buffer saline (PBS), and added to glow discharged carbon coated 200 mesh grids (for TEM). Each of the four vaccine candidates possessed particle sizes of approximately 9 to 11 nm in diameter (see Supporting Information). These vaccine particle sizes are similar to the effective peptide-based vaccine sizes reported earlier. [34] Dendritic Cell and Macrophage Uptake Assay For a vaccine candidate to be effective, it must be efficiently taken up by antigen presenting cells (particularly DCs). [21] Therefore, DC and macrophage uptake assays were performed according to the literature. [35] [36] The vaccine candidates 1a-d were labeled with Dil (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) and incubated with DCs and macrophages, which were derived from mouse splenocytes. Following incubation with Dil labeled 1a-d, the cells were labelled with CD11c-A660 and F4/80-APC-Cy7 antibodies for DCs and macrophages, respectively, and their fluorescence was measured by flow cytometry. Uptake was calculated as the percentage of cells that were double positive for Dil-labeled compound and CD11c-A660 or F4/80-APC-Cy7 (Figure 3 ).
The results indicated that uptake was consistently more efficient in DCs compared to macrophages. Although there was no statistical difference between each of the vaccine candidates, at lower concentrations uptake of compounds 1b and 1d did appear to be the more efficient than 1a and 1c.
Circular Dichroism Analysis
The M protein of GAS possesses an α-helical secondary structure, and this secondary structure is important for B cell recognition. [15] The CD spectra of the vaccine candidates 1a-d showed a varying degree of α-helicity. Each showed minima at approximately 205 nm and 222 nm, which is characteristic of an α-helical structure ( Figure 4 ). Vaccine candidate 1d displayed the most intense signal, and therefore, possessed the largest degree of α-helicity. The spectra of vaccine candidates 1b and 1c were comparable to that of 1d, while vaccine candidate 1a displayed the least intense signal, and thus, the lowest degree of α-helicity. 
ELISA Assay
Immunological evaluation was performed on inbred C57BL/6 mice. Mice (5 mice/group) were immunized subcutaneously at the tail base on day 0 with 30 µg of the vaccine candidates 1a-d, without administering an external adjuvant. The positive control group was treated with J8-CRM197/AAHSA, which is a formulation of the J8 peptide conjugated to the protein carrier Cross Reacting Material 197 (CRM197; a non-toxic analog of diphtheria toxoid), in amorphous aluminum hydroxyphosphate sulfate adjuvant (AAHSA). This formulation has recently been used by Caro-Aguilar et al., and was shown to be immunogenic in mice, as well as, in non-human primates. [37] The negative control group was administered sterile filtered PBS. Mice received two boosts of each immunogen at days 21 and 28 post-primary immunizations. Sera samples were collected prior to each boost and 11 days after the final boost, and the levels of J8-specific immunoglobulin G (IgG) were determined using ELISA. Three vaccine candidates 1b, 1c and 1d, and the positive control (J8- 
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For internal use, please do not delete. Submitted_Manuscript . J8-specific IgG titers elicited in response to vaccination of C57BL/6 mice (n = 5/group) at day 39, serum IgG antibody titer (log 10). Mice received a primary subcutaneous immunization on day 0, followed by two boosts on days 21 and 28. Samples were collected on day 39. Statistical analysis was performed by one-way ANOVA followed by the Tukey's multiple comparisons test (*** = p < 0.001; **** = p < 0.0001).
Conclusions
Four self-adjuvanting vaccine candidates, were designed and synthesized using standard SPPS in 12-32% yields. Particle size of the vaccines was determined to be 9-11 nm. Dendritic cell and macrophage uptake studies indicated that the uptake of 1d and 1b was more efficient compared to 1a and 1c. Analysis of vaccine candidate 1a by circular dichroism showed less intense minima at approximately 205 and 222 nm compared to vaccine candidates 1b, 1c and 1d. This suggested that 1a displayed a less helical secondary structure compared to the other vaccine candidates. The immunogenicity of the vaccines was evaluated by in vivo assay performed in mice to measure the IgG titers. Vaccine candidates 1b, 1c and 1d showed significant induction of IgG when compared to PBS.
Experimental Section
Materials: Dimethylformamide (DMF), diethyl ether (Et2O), acetonitrile (CH3CN), trifluoroacetic acid (TFA), piperidine, and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were obtained from Merck KgaA (Darmstadt, Germany). Dichloromethane (DCM) was purchased from Chem-Supply (Adelaide, Australia). 2-(1H-7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and all N-α-Fmoc protected amino acids were supplied by Mimotopes (Victoria, Australia). Rink amide 4-methylbenzhydrylamine (MBHA) resin was purchased from Novabiochem (Läufelfingen, Switzerland). All solvents and reagents were used as purchased, unless otherwise stated.
Equipment:
Microwave-assisted peptide couplings were performed using a CEM Discover Bio System manual peptide synthesiser (Matthews, USA). Mass spectra (MS) were obtained from a quatropol electrospray (Perkin Elmer Sciex API 3000 instrument) in the positive ion mode using Analyst 1.4 software (Applied Biosystems/MDS Sciex, Toronto, Canada). Analytical RP-HPLC was performed on a Shimadzu (Kyoto, Japan) instrument (LC-20AT liquid chromatograph, CMB-20A communication bus module, SIL-20A HT auto sampler, CTO-20 column oven, SPD-M20A diode array detector, ELSD-LT II low temperature evaporative light scattering detector, LabSolutions software), with C18 or C4 Grace Vydac® (Columbia, Maryland, USA) columns (10 µm, 4.6 mm internal diameter x 250 mm,) using a stated gradient of CH3CN/10% H2O/0.1% TFA (solvent B) and H2O/0.1% TFA (solvent A) with a 1 mL/min flow rate and detection at 214 nm.
Semi-preparative RP-HPLC was performed using a Waters Delta 600 system (Milford, Massachusetts, USA; Model 600 Controller, 490E UV Detector). Purifications were achieved using Vydac® C4 or C18 preparative columns (10 µm, 10 mm internal diameter × 250 mm) using a stated gradient quoted as % solvent B at 4 mL/min flow rate, and detection at 214 nm. Fractions containing pure compound were pooled and lyophilized overnight.
Preparative RP-HPLC was performed on a Shimadzu (Kyoto, Japan) instrument (LC-20AP liquid chromatograph, CMB-20A communication bus module, SPD-20 UV/Vis detector, FRC-10A fraction collector), with C18 or C4 Grace Vydac® (Columbia, Maryland, USA) columns (10 µm, 22 mm internal diameter x 250 mm) using a stated gradient quoted as % solvent B with a 20 mL/min flow rate and detection at 214 nm.
Dendritic cells uptake assay was performed on BD LSR II flow cytometer. CD spectra were measured on a JASCO (Tokyo, Japan) J-710 spectropolarimeter using a quartz cuvette of 1 mm path length at 23°C.
Peptide Synthesis:
Stepwise SPPS (manual and microwave-assisted) was performed using rink amide MBHA resin (substitution ratio: 0.79 mmol/g) with standard Fmoc SPPS chemistry.
Standard Fmoc SPPS Conditions:
Fmoc-amino acids (4.2 equivalents (equiv.)) were pre-activated with HATU (0.4 M in DMF, 4 equiv.) and DIPEA (6.2 equiv.). Coupling cycles consisted of Fmoc deprotection with piperidine (20% in DMF, 2 x 15 min (manual) or 2 x 2 min, 70ºC (microwave)), DMF washing, followed by coupling with pre-activated Fmoc-amino acids (2 x 30 min (manual) or 2 x 5 min, 70ºC (microwave)). Acetylation was performed by treatment with a 1:1 mixture of acetic anhydride and DIPEA (5% in DMF) for 2 x 15 min (manual) or 2 x 2 min, 70°C (microwave). After assembly of the required sequence, the peptidylresin was washed with DMF and DCM, and dried under vacuum. Peptides were cleaved from the resin by stirring in a solution of TFA, triisopropylsilane (TIPS) and H2O (95:2.5:2.5) for 3 h. The resin was removed by filtration and the excess TFA was evaporated by a stream of N2. The peptides were precipitated from ice-cold Et2O, centrifuged, and the Et2O decanted.
Glycopetide 2:
Using standard microwave-assisted Fmoc SPPS, a linear peptide was prepared with the sequence KKFVAAWTLKAAKK. FmocLys(ivDde)-OH was coupled using standard microwave-assisted Fmoc SPPS; although, the equivalents of the reagents were reduced: amino acid (2.5 equiv.), HATU (2.4 equiv.), DIPEA (4.6 equiv.). Following piperidine deprotection of the N terminus, the TPGlc (2,3,4,6-tetra-O-acetyl-1-O-(6-methoxy-6-oxohexyl)-β-D-glucopyranose) 12 carbohydrate building block (2.5 equiv. in 1 mL of DMF) and DIPEA (4.6 equiv.) were added to the resin with stirring. HBTU (2.4 equiv. in 1 mL of DMF) was added and the mixture was heated at 70°C in the microwave for 5 min. The process was repeated for a second time. The resin was washed with DMF and dilute hydrazine (7 mL, 2% in DMF) was added. The mixture was shaken for 1 h at room temperature, and the process repeated a further three times. FmocLys(Boc)-OH was coupled to the deprotected side-chain amine using standard microwave-assisted SPPS. The peptidyl-resin was washed with DMF, DCM and dried under vacuum to give the resin-bound glycopeptide 2, which was divided into four equal portions.
Glyco-lipopetide 3a:
A portion of resin-bound glycopeptide 2 (0.05 mmol) was allowed to swell in DMF for 1 h. Following Fmoc removal, the required
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Glyco-lipopetide 3b:
A portion of resin-bound glycopeptide 2 (0.05 mmol) was allowed to swell in DMF for 1 h. Following Fmoc removal, the required lipidic adjuvanting sequence (Ac-C16-C16-S-S-) was incorporated using standard manual Fmoc SPPS, unless otherwise stated. Dde-C16-OH 29 was coupled using standard coupling conditions, and the Dde group was removed by treatment with hydrazine (2% in DMF, 3 x 20 min). The sequence was capped using standard acetylation conditions. Following cleavage from the resin and precipitation, the crude glyco-lipopeptide 3b was dissolved in a minimum volume of DMF, diluted with solvent A and B (1:1, 50 mL), and lyophilized. Glyco-lipopeptide 3b was used without purification; HPLC analysis (C4 5+ calcd 600.4, found 600.9; molecular weight 2996.8 g/mol.
Glyco-lipopetide 3c:
A portion of resin-bound glycopeptide 2 (0.05 mmol) was allowed to swell in DMF for 1 h. Following Fmoc removal, the required lipidic adjuvanting sequence (Ac-K(C12)-K(C12)-G-K(C12)-) was incorporated using standard microwave-assisted Fmoc SPPS, using Fmoc-Lys(C12)-OH (K(C12)) as the lipo-amino acid. 12 The sequence was capped using standard acetylation conditions. Following cleavage from the resin and precipitation, the crude glyco-lipopeptide 3c was dissolved in a minimum volume of DMF, diluted with solvent A and B (1:1, 50 mL), and lyophilized. Glyco-lipopeptide 3c was used without purification; HPLC analysis (C4 column): tR = 28. 
Glyco-lipopetide 3d:
A portion of resin-bound glycopeptide 1 (0.05 mmol) was allowed to swell in DMF for 1 h. Following Fmoc removal, two standard Fmoc-Ser(tBu)-OH amino acid residues were coupled using standard manual Fmoc SPPS. The non-standard amino acid Fmoc-Ser-OH was coupled by the addition of Fmoc-Ser-OH (4.2 equiv. in 1 mL of DMF) and DIPEA (6.2 equiv.) to the resin with stirring, followed by the addition of HBTU (4 equiv. in 1 mL of DMF). The mixture was rotated for 30 min, and the process was repeated. The resin was washed with DMF and the Fmoc group removed. DIC (156 µL, 1.0 mmol, 20 equiv.) was added to a solution of palmitic acid (0.513 g, 2.0 mmol, 40 equiv.) and DMAP (42.8 mg, 0.4 mmol, 7 equiv.) in 5 mL of DMF, and the mixture was allowed to preactivate for 10 min. The pre-activated solution was added to the resin and the mixture was rotated at room temperature overnight (approx. 16 h). The resin was washed with DMF, DCM and dried. Following cleavage from the resin and precipitation, the crude glyco-lipopeptide 3d was dissolved in a minimum volume of DMF, diluted with solvent A and B (1:1, 50 mL), and lyophilized. Glyco-lipopeptide 3d was used without purification; HPLC analysis (C4 column): tR = 33. 
General Procedure for Synthesis of Vaccine Candidates 1a-d:
Crude glyco-lipopeptide 3a-d (2 mg) and N3-J8 12 (8 mol equiv.) were dissolved in DMF (2 mL) and copper wire (approx. 200 mg) was added. The mixture was stirred at 50°C under nitrogen until a blue/green color was distinguishable (approx. 1-2 h), at which point the reaction was cooled in a bath of dry ice. The copper wire was removed by filtration and the DMF filtrate was loaded directly onto a preparative C4 column (RP-HPLC). The vaccine candidate was eluted with a gradient of 0% for 28 min, 0-20% over 2 min, and 20-60% solvent B over 60 min. Particle Size Analysis by DLS: The sample compound was prepared in PBS (60 µM) and transferred to a low-volume disposable plastic cuvette. Particle sizes were measured and analyzed with Zetasizer software on a Zetasizer Nano ZP instrument (Malvern Instruments, UK). Sample size measurements were carried out using the M3-PALS technique at 25ºC with a backscattering angle of 173º. Measurements were performed in triplicates and the average size by number was reported.
Vaccine
Particle Size Analysis by TEM:
The sample compound was dissolved in PBS (60 µM) and 50 µl was added to glow discharged carbon coated 200 mesh grids for 3 min and excess liquid was wicked off with filter paper. Pictures were taken using a JEM-1010 transmission electron microscope (JEOL Ltd., Japan) operated at 80 kV.
Dendritic Cell and Macrophage Uptake Assay:
The uptake assays were performed according to previous studies. 32, 33 Briefly, mouse spleens were passed through a 70 µm cell strainer, and the strainer was rinsed with PBS (40 mL). The cells were centrifuged (310 g, 10 min, 4°C) and the 10.1002/cbic.201600639 ChemBioChem supernatant was discarded. Erythrocyte lysis buffer (5 mL) (Sigma-Aldrich, Sydney, Australia) was added, and the cells were cooled to 0°C for 7 min. The cells were washed and centrifuged (as above) twice with PBS (2 x 35 mL). The cells were resuspended in PBS (1 mL), plated on a 24 well round bottom plate (2 x 10 5 / well) in phenol free IMDM Glutamax medium (Gibco, Life Technologies, Melbourne, Australia) and incubated at 37°C for 4 h. The media was supplemented with 10% FBS, 50 μM 2-mercaptoethanol (Gibco, Life Technologies), 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, Life Technologies).
The vaccine candidates 1a-d (100 μL, 50 µM in PBS) were labelled with 0.5 μL of Dil (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate) (Vybrant, Life Technologies) by incubating at 4°C for 30 min. Cells were incubated with Dil-labelled compounds overnight at 37°C. The cells were removed from the plate and centrifuged (650 g, 5 min, 4°C). Cells were resuspended in 40 μL Fc receptor block (eBioscience, San Diego), incubated for 10 min at 4°C and centrifuged (as above). The cells were washed and centrifuged (as above) with FACS buffer (PBS, 0.02% sodium azide, 0.5% BSA) (3 x 50 µL). The cells were resuspended in 50 μL of fixation buffer (eBioscience) and incubated for 20 min at room temperature. After fixation, the cells were washed and centrifuged (as above) with FACS buffer (3 x 100 μL), resuspended in 0.5 mL of FACS buffer, and analyzed using LSR II flow cytometry (BD Biosciences, San Jose, California). Dendritic cells and macrophages were also treated with PBS and Dextran-FITC (Chondrex, Inc., USA), and the fluorescent intensities were measured as negative and positive controls, respectively. The uptake was calculated as the percentage of cells double positive for conjugate (Dil) and CD11c (A660) or conjugate (Dil) and F4/80 (APC-Cy7) markers.
Preparation of J8-CRM/alum Conjugate: [37] Purified CRM carrier protein was obtained from Merck Research Laboratories (Kenilworth, New Jersey), and activated for conjugation by the addition of maleimide groups to surface-accessible lysine residues using the heterobifunctional crosslinking reagent succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC, Thermo Fisher Scientific, Rockford, IL). Briefly, a concentrated stock of CRM in phosphate buffer was diluted in 20 mM HEPES, 0.15 M NaCl, 0.005 M EDTA, pH 7.3 to a total protein concentration of 1 mg/mL. 9 mg of SMCC (10-fold molar ratio to theoretical CRM lysine content) was dissolved in 1 mL of dry dimethyl sulfoxide (DMSO) and added to the CRM solution while it was being gently vortexed. The reaction mixture was incubated in the dark at room temperature for 3 h. The sample was then reduced in volume to 5 mL using an Amicon Ultra centrifugal concentrator and desalted over a Hi Prep 26/10 desalting column (GE Healthcare Life Sciences, Parramatta, Australia) equilibrated in 20 mM HEPES, 0.15 M NaCl, 5 mM EDTA, pH 7.3. The amount of maleimide incorporated into the CRM was determined using a 5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB)-based assay, which relies on the consumption of a fixed amount of N-acetyl cysteine from a standard solution. CRM total protein was determined by the bicinchoninic acid (BCA) protein assay. Conjugation of thiolated J8 peptide to maleimideactivated CRM was performed at a 2:1 molar ratio of peptide thiol to CRM maleimide. The required amount of thiolated J8 peptide was weighed out and placed in a 20 mL glass vial, to which the activated CRM solution was added. The solution was mixed to ensure that the peptide was completely dissolved, and then incubated overnight at room temperature. The conjugate was purified of un-reacted peptide by size exclusion chromatography over a 2.5 by 45 cm Superdex 30 column equilibrated and run in 20 mM HEPES, 0.15 M NaCl, pH 7.3. The molar loading ratio of peptide to carrier was determined by quantitative amino acid analysis using least squares linear regression analysis and quantitation of unique amino acid residues generated during the conjugation reaction. [38] The adjuvants used for formulation was amorphous aluminum hydroxyphosphate sulfate (AAHSA; Merck Manufacturing Division, West Point, PA).
Subcutaneous Immunization of Mice:
Eight week-old female inbred C57BL/6 mice were used in this study (Animal Resource Centre, Western Australia). All animal protocols used were approved by the Animal Ethics Committee (The University of Queensland), in accordance with National Health and Medical Research Council (NHMRC) of Australia guidelines. Access to food and clean water was provided ad libitum.
Cohorts of 5 mice were subcutaneously immunized at the base of the tail with 30 µg of vaccine candidates 1a-d dissolved in 50 µL of sterile PBS (Griffith University, Gold Coast, Australia). Similarly, a negative control group was administered 50 µL of PBS and a positive control received 30 µg of J8-CRM197/AAHSA (total volume of 50 µL). Boosts of the same dosage were given on days 21 and 28 following primary immunization. Determination of Antibody Titers: Detection of serum IgG antibodies against the J8 epitope was performed using ELISA, as previously reported. [39] Briefly, ELISA plates were coated with J8 (10 mg/mL) in carbonate coating buffer overnight at 4°C and blocked with 150 µL/well of 5% skim milk for 90 min at 37°C. Serial dilutions of collected sera were prepared in 0.5% skim milk/PBS-Tween-20 buffer, starting at a concentration of 1:100, followed by 1:2 dilutions. Absorbance values were read at 450 nm in a microplate reader after the addition of the secondary antibody (peroxidase-conjugated antimouse IgG) and Ophenylenediamine. The antibody titer was identified as the lowest dilution that gave an absorbance of more than 3 standard deviations above the mean absorbance of control wells (containing normal mouse serum). Statistical analysis (p < 0.05 = statistical significance) was performed with one-way ANOVA followed by Tukey's post hoc test.
